GET DAILY SIGNALSGinkgo Bioworks (DNA): Is a +60% Move to $18 Feasible?
Key Takeaways
- The central $18 target is not an analyst consensus. It reflects DNA's recent 52-week high of $18.22, a technical milestone the stock touched in early October 2026.
- Published analyst price targets actually sit below the current price, ranging from roughly $5 (BTIG) to $11 (TD Cowen), with an average near $8 — a "Sell"-leaning setup.
- With DNA last trading around $11.21, reaching $18 would require a gain of roughly 60%, a very large move.
- Supporting factors include a debt-light balance sheet (about $474 million in cash), aggressive cost reductions, and AI-linked life-sciences demand; the main risks are sharply declining revenue, persistent losses, and limited near-term growth visibility.
- For additional context on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
- To monitor shifting AI-driven opportunities across the market, explore Trending AI Robots.
Analyst Context and How the $18 Target Came Into View
Ginkgo Bioworks Holdings, Inc. operates a synthetic-biology platform that programs cells for use in pharmaceuticals, agriculture, and industrial materials. It is a single stock, best evaluated on its own fundamentals amid very limited sell-side coverage.
Current analyst targets remain cautious and sit below the latest price. BTIG reiterated a $5 Sell rating in September 2026, while TD Cowen raised its target to $11 (Hold) from $9 on October 13, 2026. William Blair maintains a Sell rating without a public price target. Aggregators polling three analysts show a range of about $5 to $11 and an average near $8, pointing to downside rather than upside from the recent $11.21 level.
Because no published analyst target sits meaningfully above the market price, the $18 figure functions as a fallback technical objective drawn from market structure. It aligns with DNA's 52-week high of $18.22, briefly reached on October 6, 2026, during a high-volume surge. In short, $18 marks a potential retest of that recent high rather than any formal consensus forecast.
Current Market Position and the Path to $18
DNA last traded near $11.21, well above its $5.37 52-week low yet still about 38% below the October peak. Reaching $18 would require roughly a 60% advance from here — a substantial move even for a stock that has already shown extreme volatility.
The route depends more on renewed momentum than on a steady earnings improvement. The company posted a second-quarter 2026 EPS of negative $0.75 (beating estimates) while revenue of about $20.2 million missed expectations. Full-year 2026 revenue is expected to decline sharply. Its cash position of roughly $474 million and absence of bank debt provide runway, yet do not generate growth on their own. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Factors That Could Support a Move Higher
TD Cowen’s October target increase highlighted one of the strongest quarters in 20 years for the life-sciences-tools sector, supported by biotech funding, AI-related demand, and better commercial execution. Ginkgo’s cost-cutting efforts have narrowed losses, and its cash-rich, debt-light balance sheet lowers near-term solvency concerns. An earnings beat, new partnership announcements, or renewed interest in AI-adjacent synthetic-biology themes could help sentiment recover toward prior highs.
Obstacles That Could Keep the Target Out of Reach
Revenue is contracting sharply, with expectations pointing to roughly a 50% decline in 2026, and the company remains deeply unprofitable on both EPS and EBITDA measures. Analysts have noted limited visibility on near-term growth and revenue recognition, which prompted the earlier downgrade to Hold. With a consensus rating near “Sell” and every published target at or below the current price, fundamental support from the sell side is absent. The stock’s volatility — dropping from an intraday high of $18.22 in early October to the low $11 range weeks later — shows how quickly sentiment can shift.
Technical Levels and Market Structure
The $18.22 print from October 6, 2026, defines the key resistance level. Below it, DNA has traded in a wide range, with the $10-to-$11 zone serving as near-term support and the $5.37 low marking deeper support. A sustained move back above the mid-teens would be needed before any credible test of the $18 area, while a break below the low teens could reopen the path toward single digits.
Time Horizon and Items to Watch
Because the $18 level is a technical benchmark rather than an analyst target, it carries no fixed research horizon. The next meaningful catalyst is the third-quarter earnings report scheduled for November 5, 2026. Key items to monitor include revenue versus expectations, any revised full-year guidance, commentary on cost reductions and cash burn, new platform or partnership updates, and further analyst rating changes. Broader biotech funding conditions and sentiment around AI-linked life-sciences themes will also influence the stock given its rapid repricing history.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI analysis. For a volatile name such as DNA, these signals can help identify emerging momentum changes, track existing positions, and review new opportunities more efficiently than manual chart work. I find them useful for staying on top of fast-moving names without constant screen time.
Final Assessment
Whether Ginkgo Bioworks stock can reach $18 ultimately hinges on whether the early-October optimism can reappear. The $18 objective is a technical milestone tied to the 52-week high, not a published analyst forecast — and that distinction is important because the actual analyst view remains cautious, with targets of roughly $5 to $11 and an average near $8 that sits below the current price. A move to $18 would require about a 60% advance, which is substantial and would need renewed momentum, clearer revenue visibility, and continued sector enthusiasm. The company’s cash position and cost discipline offer a foundation, yet falling sales, ongoing losses, and limited near-term visibility present real hurdles. Investors should focus on the November earnings report and any analyst revisions as the next checkpoints, without viewing the $18 level as a prediction or recommendation.
Promo Section
I rely on Tickeron’s AI Daily Buy/Sell Signals as part of my regular workflow to scan for momentum shifts across volatile names. The platform’s AI-driven approach helps surface signals based on technical and market-condition changes, which I cross-reference with fundamental updates when evaluating names like DNA. It fits naturally into a broader research routine without replacing manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on DNA as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for DNA just turned positive on October 29, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +32.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 90 of 109 cases where DNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where DNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.796) is normal, around the industry mean (3.162). P/E Ratio (-2.242) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement